Compare ASMB & HKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ASMB | HKD |
|---|---|---|
| Founded | 2005 | 2003 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 440.0M | 499.7M |
| IPO Year | 2010 | 2021 |
| Metric | ASMB | HKD |
|---|---|---|
| Price | $29.34 | $1.82 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $44.20 | N/A |
| AVG Volume (30 Days) | 71.8K | ★ 194.8K |
| Earning Date | 05-07-2026 | 02-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 91.78 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $235.63 | N/A |
| P/E Ratio | ★ N/A | $14.10 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.82 | $1.26 |
| 52 Week High | $39.71 | $5.47 |
| Indicator | ASMB | HKD |
|---|---|---|
| Relative Strength Index (RSI) | 53.18 | 66.62 |
| Support Level | $29.31 | $1.58 |
| Resistance Level | $30.54 | $1.88 |
| Average True Range (ATR) | 1.41 | 0.10 |
| MACD | 0.11 | 0.02 |
| Stochastic Oscillator | 70.11 | 85.39 |
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.
AMTD Digital Inc along with its subsidiaries, is mainly involved in the provision of digital solutions services. Its reportable segments are digital solutions services segment; hotel operations, hospitality and VIP services segment; media and entertainment services segment; and Strategic investments. The company generates maximum revenue from Digital solutions services segment, which provides its institutional and corporate clients with exclusive, paid access to enhance their investor communication, investor relations and corporate communication to potentially maximize their valuation, as well as providing digital solution services. Geographically, the company generates revenue from China, Hong Kong, Europe, Americas and Southeast Asia.